Table 1. Basic clinical features of the 16 included studies.
| Study | Age, years | Gender (male) | Disease type | E | C | Research type |
|---|---|---|---|---|---|---|
| Kawai et al., 2018 (11) | 63.71±12.2 | 41.25% | Primary liver cancer | 30 | 45 | Cohort |
| Wang et al., 2017 (12) | 54.65±12.4 | 61.11% | Primary liver cancer | 48 | 42 | RCT |
| Lim et al., 2021 (13) | 63.12±14.5 | 45.72% | Primary liver cancer | 49 | 44 | Cohort |
| Zhang et al., 2020 (14) | 55.7±11.2 | 81.25% | Liver cancer | 30 | 34 | Cohort |
| Velayutham et al., 2016 (15) | NR | 55.00% | Primary liver cancer | 20 | 40 | Cohort |
| Zhu et al., 2016 (16) | 53.7±13.3 | 67.39% | Primary liver cancer | 22 | 24 | Cohort |
| Park et al., 2019 (17) | 57.25±16.0 | 66.34% | Donor | 6 | 13 | RCT |
| Zhang et al., 2021 (18) | 68.12±2.5 | 66.22% | Primary liver cancer | 44 | 41 | Cohort |
E, experimental group; C, control group; RCT, randomized controlled trial; NR, not reported.